Gosselies, Belgium, Europe
Viral vector development and analytical facility
Thermo Fisher Scientific’s Gosselies facility, located in the heart of Belgium’s largest biotech hub, is dedicated to developing viral vectors (process and analytical) for clinical applications.
The facility has 400 square meters of R&D space, and 380 square meters of classified cGMP space staffed by industry experts in the development of viral vectors, viruses, vaccines, and other therapies. The facility ensures a lean and efficient transfer from viral vector development to cGMP manufacturing.
Gosselies is part of our European network of viral vector sites, which includes Seneffe, Belgium, and part of our global network, including Cambridge and Plainville, MA in the US.
Key Capabilities:
- Experience in viral vector and virus development for cell and gene therapies, vaccine applications and other therapies.
- Process and analytical development
- Broad array of adherent and suspension processes
- Small- to mid-scale: up to 200L
| Process Development | ||||||||||||
| Process Characterization | ||||||||||||
| Process Development |
To learn more about this location, download the site capabilities factsheet.
Helpful Resources
Infographic
Infographic
Regulatory pathways for CGT and ATMP products
CGT is one of the world's fastest-growing therapeutic areas today. Instead of treating patients for the rest of their lives, these therapies offer them hope of a cure. In this infographic, we will review three tips for achieving regulatory success.
View Infographic
eBook
eBook
Cell and gene therapies in the US vs. the EU: Top five areas of differentiation
In this eBook we share the five key differences in the drug development and review process for companies hoping to gain market access through US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval—as well as tips for navigating these differences.
Blog post
Blog post
Product and partnership quality in viral vector manufacturing: Your gene therapy depends on it
Viral vectors are inherently complex to produce at scale, requiring a laser focus on quality to ensure the efficiency, safety, targeted delivery, and scalability of the gene therapy.
View Blog Post
Article
Article
From early innovations to commercial triumphs: One viral vector partner for every stage of gene therapy development
Our article explores the partnership needs of two companies at opposite ends of the continuum for gene therapy development and how both—NysnoBio and bluebird bio—found the support they were looking for to deliver their innovative therapies to patients.
Read Article